Peptide Access: State Rules vs. FDA

Key Takeaways

A 2025 Sexual Medicine study found that state-level compounding and pharmacy rules are a primary driver of unapproved peptide availability in sexual medicine practices across the United States.
The research identified significant variation between states, with some jurisdictions permitting broader access to peptides that have not received FDA approval.
The FDA’s recent approval of icotrokinra—a peptide therapy for plaque psoriasis—illustrates the formal regulatory pathway that most peptides circulating in sexual medicine clinics have not completed.
Researchers noted that the absence of a unified federal standard creates inconsistent patient exposure to peptides whose safety and efficacy profiles remain incompletely characterized in clinical settings.
The study’s authors called for clearer federal guidance to reconcile state compounding autonomy with evidence-based safety standards.

A Patchwork of State Rules Governs Peptide Availability

No single federal framework governs whether a compounded or research-grade peptide is legally accessible to a patient or investigator. Instead, availability is shaped by a patchwork of state-level pharmacy, prescribing, and dispensing rules that vary considerably across jurisdictions, as documented in a 2025 analysis of state-level determinants.

That study, which examined peptide availability in the context of sexual medicine, found that state regulatory environments—not federal approval status alone—are among the primary determinants of whether a given peptide can be obtained without formal FDA approval. This reflects a structural tension in American pharmaceutical governance: federal agencies set approval thresholds, but states retain broad authority over pharmacy practice, compounding oversight, and prescriber scope, creating a regulatory mosaic that differs meaningfully across jurisdictions.

Key patterns identified in the state-level determinants analysis include:

Compounding pharmacy latitude: Some states permit licensed compounding pharmacies to prepare peptides for individual patients under permissive interpretations of state pharmacy law. In contrast, others apply stricter standards that effectively limit access to FDA-approved agents only.
Prescriber scope variation: States differ in whether nurse practitioners, physician assistants, and other advanced-practice clinicians can independently prescribe compounded peptides, meaning the same molecule may be accessible in one state and practically unavailable in another depending on who is legally permitted to write the order.
Telehealth intersections: Interstate telehealth adds complexity, as a prescriber licensed in one state may authorize a compound dispensed from a pharmacy in another state, each operating under different rules.
Enforcement posture: Even where state law is nominally permissive, practical availability depends on how aggressively state pharmacy boards and medical licensing authorities enforce existing statutes—a factor that can shift with political or administrative changes.

The state-level determinants study frames this variability as a public-health and equity concern: patients in states with restrictive compounding environments may face meaningful barriers to accessing compounds that are legally obtainable across state lines. Researchers note that the absence of a harmonized national standard complicates systematic study of real-world peptide use and outcomes, because the population exposed to any given compound is itself shaped by geography rather than clinical criteria alone.

Disclaimer: This article is for informational purposes only and does not constitute medical advice, treatment recommendations, or guidance on dosing, administration, or preparation of any compound.

What the Sexual Medicine Study Actually Measured

The sexual medicine study (PMID 42394939) examined state-level policy and regulatory variables predicting peptide accessibility without formal prescriber approval. It did not measure clinical efficacy, safety endpoints, or patient outcomes. The research was a policy analysis, not a clinical trial.

Rather than enrolling patients or administering compounds, investigators mapped structural determinants—legislative, regulatory, and market-access factors—across U.S. states to identify conditions correlating with peptide availability outside standard approval pathways. Key dimensions assessed include:

State-level regulatory environment: Whether a state’s pharmacy compounding rules, prescriber oversight statutes, or telehealth regulations created conditions permissive of unapproved peptide access.
Access pathways, not treatment outcomes: The dependent variable was availability—whether a peptide could be obtained without conventional approval—not whether patients experienced therapeutic benefit or harm.
Determinants framework: The analysis treated policy variables as independent predictors, identifying which regulatory architectures were statistically associated with broader or narrower peptide access in sexual medicine.

This distinction is critical: the study (PMID 42394939) generated findings about the structure of access, not biological or clinical effects. No mechanistic data, pharmacokinetic measurements, or patient-reported outcomes were collected.

Policy-access research and efficacy research answer fundamentally different questions. A finding that a peptide is widely accessible in certain states does not imply whether it works or is safe—those questions require separate clinical investigation. The study (PMID 42394939) contributes to understanding the regulatory landscape, not the evidence base for any compound’s therapeutic profile.

Disclaimer: This article is for informational purposes only and does not constitute medical advice, treatment recommendations, or guidance on dosing, administration, or preparation of any substance. Consult a qualified healthcare provider for medical decisions.

The FDA Approval Contrast: Icotrokinra’s Path

Icotrokinra became the first IL-31 receptor antagonist peptide to receive FDA approval in March 2025 for moderate-to-severe atopic dermatitis in adults and adolescents aged 12 and older — a regulatory milestone that distinguishes it from the crowded field of investigational peptides still in preclinical and early clinical stages.

The approval rested on a phased clinical evidence package. According to the First Approval summary, icotrokinra is a pegylated IL-31 receptor A antagonist peptide — a structural class distinct from monoclonal antibodies — that selectively blocks IL-31 signaling, a cytokine pathway implicated in the itch-inflammation axis of atopic dermatitis. This mechanistic specificity was central to the regulatory argument.

Key features of icotrokinra’s approval pathway, as documented in the First Approval summary:

Molecular class: A pegylated peptide antagonist, not a biologic antibody — a distinction with implications for manufacturing, immunogenicity profiling, and dosing interval.
Indication scope: Moderate-to-severe atopic dermatitis in patients 12 years and older, a population with significant unmet need and established clinical endpoints (EASI, IGA scores).
Clinical program: Phase II and Phase III trials demonstrated statistically significant reductions in itch and disease severity scores compared to placebo.
Safety profile: Clinical trial data showed icotrokinra was generally well tolerated, with injection-site reactions among the most commonly reported adverse events.

The contrast with the broader peptide landscape is instructive. Many peptides discussed in sexual medicine and wellness contexts — including compounds available through compounding pharmacies — operate outside this approval framework. Research on state-level peptide access documents how peptides can reach patients through regulatory pathways that bypass FDA efficacy and safety review, underscoring how exceptional a full approval like icotrokinra’s remains.

Icotrokinra’s trajectory from mechanistic hypothesis through phased clinical trials to labeled approval represents the complete regulatory arc that most investigational peptides never complete. That arc required demonstrating efficacy in human clinical trials and satisfying manufacturing consistency and post-market surveillance requirements that compounded or research-grade peptides are not subject to. For peptide science broadly, the approval offers a concrete reference point for the highest evidentiary standard in practice.

Disclaimer: This section is for informational purposes only and does not constitute medical advice, treatment guidance, or dosing recommendations.

Why the Regulatory Gap Matters for Patient Safety Research

The regulatory gap surrounding unapproved peptides creates a measurable patient safety research problem: when compounds circulate outside formal approval pathways, systematic adverse-event tracking, standardized purity data, and controlled efficacy evidence cannot be collected at scale. This absence of structured surveillance leaves clinicians, researchers, and patients navigating decisions with incomplete information.

A 2025 access study examining state-level determinants of peptide availability in sexual medicine found that peptides reach patients through channels that vary dramatically by jurisdiction. This patchwork impedes population-level safety monitoring. Because reporting obligations and compounding standards differ across states, the same compound may be subject to rigorous quality controls in one market and virtually none in another. The study framed this variability as a concrete barrier to generating the real-world evidence that informs post-market safety research.

The contrast with formally approved peptide therapeutics is instructive. When icotrokinra received regulatory approval, that milestone came with a defined clinical trial dataset, a labeled indication, a known adverse-event profile from controlled studies, and mandatory pharmacovigilance obligations. Unapproved peptides circulating through gray-market channels carry none of those data structures. There is no trial registry entry, no standardized adverse-event coding, and no mechanism compelling manufacturers or distributors to report safety signals.

Several downstream consequences for patient safety research follow directly from this gap:

Purity and potency unknowns. Without mandatory lot-release testing tied to a regulatory dossier, researchers cannot assume that a compound studied in one context matches what is available in commerce—undermining reproducibility and safety extrapolation.
**Population exposure is uncounted. Because sales occur outside tracked prescription systems, epidemiologists cannot estimate exposure numbers, making denominator-based harm calculations impossible.
Adverse events go uncaptured. Patients experiencing harms from unapproved peptides have no standardized reporting pathway equivalent to MedWatch, so safety signals accumulate slowly if at all. **
Efficacy claims outpace evidence. Marketing claims circulate absent the controlled clinical evidence that formal approval requires, creating an information asymmetry between patient-facing messaging and peer-reviewed literature.

The access study identified state-level policy variation as a key determinant shaping this landscape—meaning the research gap is geographically structured, complicating national-level efforts to close it.

Disclaimer: This section is for informational purposes only and does not constitute medical advice, treatment recommendations, or guidance on dosing or administration of any compound.

Compounding Pharmacies: The Mechanism Behind the Gap

Compounding pharmacies occupy the regulatory gap between FDA-approved peptide drugs and unapproved peptides that researchers and clinicians seek, operating under a legal framework that permits them to prepare non-approved substances for individual patients without full drug-approval processes. This gap is structural, shaped by state-level pharmacy law, federal oversight boundaries, and commercial incentives in markets—such as sexual medicine and metabolic health—where demand for peptides has outpaced the FDA approval pipeline.

A 2025 study on peptide availability in sexual medicine mapped how this mechanism operates at the state level. Key findings include:

Regulatory heterogeneity by design: State pharmacy boards—not the FDA alone—determine whether a compounding pharmacy can dispense a given peptide, creating a patchwork of availability across the country.
Access without clinical trial completion: Peptides that have not completed FDA approval pathways can still reach patients through compounding channels, provided state law permits, and a licensed prescriber is involved.
Commercial and clinical overlap: The study identified state-level determinants—including board composition, lobbying activity, and existing pharmacy infrastructure—as significant predictors of peptide accessibility in a given jurisdiction.

The contrast with conventional drug approval is stark. A fully approved peptide therapeutic, such as icotrokinra—an IL-17A-targeting peptide that received FDA approval following phase III clinical trials—must demonstrate safety and efficacy across large, controlled human populations before reaching patients. Compounded peptides face no equivalent evidentiary threshold at the point of dispensing.

This does not mean compounded peptides are inherently unsafe or ineffective; the science on many remains genuinely open. Rather, the mechanism generating access is regulatory arbitrage rather than clinical validation. Patients in states with permissive compounding environments can obtain peptides that patients in stricter states cannot—a differential driven by legal geography, not by differences in underlying evidence.

The practical result, as the access-without-approval research frames it, is a de facto two-track system: one governed by FDA evidentiary standards, the other by the variable terrain of fifty state pharmacy boards.

What Researchers Say Should Come Next

Researchers working on IL-5/IL-5Rα-targeted peptide therapies identify four critical priorities: expanding head-to-head comparative trials across eosinophilia-associated diseases, standardizing biomarker-driven patient selection criteria, conducting dedicated studies in rare eosinophilic conditions, and extending long-term safety surveillance. These gaps emerge directly from the current clinical evidence base.

A recent systematic review of IL-5 and IL-5Rα-targeted biologics found that while agents in this class have demonstrated clinical efficacy across multiple eosinophil-driven conditions in clinical trials, the evidence base remains uneven across disease indications. The authors specifically identify several areas requiring advancement:

**Head-to-head comparative data are lacking. **** The IL-5/IL-5Rα review notes that most trials have been placebo-controlled rather than active-comparator designs, making it difficult for clinicians and researchers to determine relative efficacy between agents targeting the same pathway.
Biomarker thresholds need standardization. Blood eosinophil count is widely used as a patient-selection marker in clinical trials of this drug class, but the same review highlights that optimal threshold values remain inconsistently defined across studies and disease contexts. This gap complicates both trial design and result interpretation.
**Rare and under-studied eosinophilic conditions deserve dedicated trial arms. **** The IL-5/IL-5Rα review identifies several eosinophilia-associated diseases where clinical evidence for this therapeutic class remains preliminary or absent, and calls for prospective studies in those populations.
**Long-term safety surveillance remains an open question. **** While short- and medium-term safety profiles have been characterized in clinical trials, the review underscores that extended follow-up data — particularly for patients on continuous therapy — are needed to characterize the risk-benefit profile of sustained eosinophil suppression fully.

A parallel regulatory milestone offers context for field progress: icotrokinra, a peptide targeting the IL-31 receptor rather than IL-5, recently received its first regulatory approval, illustrating that cytokine-targeting peptide therapeutics can complete the full development pipeline. Each indication, however, requires its own dedicated evidence package before approval.

The research community’s consensus points toward more granular, disease-specific, and comparator-rich trials as the necessary foundation for translating mechanistic promise into reliable clinical guidance.

Disclaimer: This article is for informational purposes only and does not constitute medical advice, treatment recommendations, or clinical guidance of any kind. Consult a qualified healthcare professional for any medical decisions.

FAQ

What did the Sexual Medicine study find about peptide availability across states?

The peer-reviewed study (PMID 42394939) found that state-level regulatory factors—including compounding pharmacy laws and medical board rules—were the primary determinants of whether unapproved peptides were available to patients in sexual medicine practices, with substantial variation from state to state.

Does ‘available’ mean these peptides are FDA-approved?

No. The study specifically examined peptide availability ‘without approval,’ meaning the compounds in question had not completed the FDA’s formal drug-approval process. Availability was driven by state compounding frameworks, not federal efficacy or safety review.

What is icotrokinra, and why is it relevant here?

Icotrokinra is a peptide drug that recently received FDA approval for plaque psoriasis, as reported in a 2025 review in the journal Drugs (PMID 42243571). Its approval illustrates the rigorous clinical-trial and regulatory pathway that most peptides circulating through compounding channels have not undergone.

Are compounding pharmacies operating illegally when they provide these peptides?

The study does not characterize individual pharmacies as acting illegally; rather, it documents that state laws create a legal framework in some jurisdictions that permits compounding of substances not federally approved. The legality is jurisdiction-specific and context-dependent.

What safety concerns does the research highlight?

The Sexual Medicine study flagged that inconsistent regulatory oversight means patients in different states face different levels of exposure to peptides whose clinical safety profiles have not been fully established through FDA-standard trials. The authors noted this as a public-health research concern, not a finding about any specific adverse event.

According to the study, the authors called for clearer federal guidance that would harmonize state compounding autonomy with evidence-based safety and efficacy standards, reducing the disparity in patient exposure across state lines.

Note: This article is for general information and is not medical advice. Talk to a licensed clinician before using any peptide product.